Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Cyclin-Dependent Kinase 4”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT04750928
What this trial is testing

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

Who this might be right for
Neurofibromatosis 1
National Cancer Institute (NCI) 55
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06849947
What this trial is testing

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

Who this might be right for
Breast Cancer Metastatic
Yeon Hee Park 272
Not applicableApproved For MarketingNCT04504513
What this trial is testing

Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer

Who this might be right for
Myelosuppression AdultChemotherapeutic ToxicitySmall Cell Lung Cancer
G1 Therapeutics, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT07227233
What this trial is testing

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

Who this might be right for
Breast Cancer
University of California, San Diego 105
Early research (Phase 1)Study completedNCT05923411
What this trial is testing

Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults

Who this might be right for
Healthy Participants
Pfizer 113
Post-approval studies (Phase 4)UnknownNCT05191914
What this trial is testing

Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors

Who this might be right for
Breast Cancer
Liaoning Cancer Hospital & Institute 20
Large-scale testing (Phase 3)Not Yet RecruitingNCT06996093
What this trial is testing

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

Who this might be right for
Breast Cancer
Fudan University 2,508
Early research (Phase 1)Study completedNCT01188252
What this trial is testing

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies

Who this might be right for
Neoplasms
Bayer 112
Early research (Phase 1)Study completedNCT05538572
What this trial is testing

PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

Who this might be right for
Breast CancerGlioblastomaHead and Neck Squamous Cell Carcinoma+4 more
Prelude Therapeutics Incorporated 22
Early research (Phase 1)Study completedNCT04124653
What this trial is testing

Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-06842874 in Healthy Participants

Who this might be right for
Healthy Participants
Pfizer 44
Testing effectiveness (Phase 2)Study completedNCT01536743
What this trial is testing

A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression

Who this might be right for
Ovarian Epithelial Carcinoma
Jonsson Comprehensive Cancer Center 26
Testing effectiveness (Phase 2)Ended earlyNCT04863248
What this trial is testing

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)

Who this might be right for
Metastatic Non-Small Cell Lung CancerNSCLCLung Cancer
G1 Therapeutics, Inc. 10
Not applicableStudy completedNCT07498413
What this trial is testing

Epidemiology and Treatment of HR+/HER2- Breast Cancer in England

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 218,677
Testing effectiveness (Phase 2)Study completedNCT03227328
What this trial is testing

CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO

Who this might be right for
Hormone Receptor Positive Breast CancerMetastatic Breast CancerHormone Receptor Negative Breast Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 52
Not applicableActive Not RecruitingNCT07008508
What this trial is testing

Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study

Who this might be right for
Breast Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 300
Large-scale testing (Phase 3)Ended earlyNCT04607668
What this trial is testing

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):

Who this might be right for
Colorectal Cancer MetastaticMyelosuppression-AdultChemotherapeutic Toxicity
G1 Therapeutics, Inc. 326
Testing effectiveness (Phase 2)Study completedNCT01291017
What this trial is testing

Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.

Who this might be right for
Non-small Cell Lung Cancer
University of Florida 19
Early research (Phase 1)Study completedNCT01335256
What this trial is testing

Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies

Who this might be right for
Neoplasms
Bayer 10
Testing effectiveness (Phase 2)Looking for participantsNCT07427394
What this trial is testing

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
AstraZeneca 24
Large-scale testing (Phase 3)Study completedNCT01864746
What this trial is testing

Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery

Who this might be right for
Breast CancerHormonreceptor PositiveHer2-normal+2 more
GBG Forschungs GmbH 1,250
Next Page